EP3423094A4 - Gfral receptor therapies - Google Patents

Gfral receptor therapies Download PDF

Info

Publication number: EP3423094A4
Authority: EP; European Patent Office
Prior art keywords: receptor therapies; gfral receptor; gfral; therapies; receptor
Prior art date: 2016-02-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16891935.5A

Other languages

German (de)

French (fr)

Other versions

EP3423094A1 (en

Inventor

Xinle Wu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-29

Filing date

2016-02-29

Publication date

2019-11-06

2016-02-29 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2019-01-09 Publication of EP3423094A1 publication Critical patent/EP3423094A1/en

2019-11-06 Publication of EP3423094A4 publication Critical patent/EP3423094A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Nutrition Science (AREA)
Biophysics (AREA)
Child & Adolescent Psychology (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP16891935.5A 2016-02-29 2016-02-29 Gfral receptor therapies Withdrawn EP3423094A4 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/CN2016/074809 WO2017147742A1 (en)	2016-02-29	2016-02-29	Gfral receptor therapies

Publications (2)

Publication Number	Publication Date
EP3423094A1 EP3423094A1 (en)	2019-01-09
EP3423094A4 true EP3423094A4 (en)	2019-11-06

Family

ID=59742416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16891935.5A Withdrawn EP3423094A4 (en)	2016-02-29	2016-02-29	Gfral receptor therapies

Country Status (4)

Country	Link
EP (1)	EP3423094A4 (en)
JP (1)	JP2019510739A (en)
CN (1)	CN108697795A (en)
WO (1)	WO2017147742A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103533951B (en)	2011-04-08	2017-04-19	安姆根有限公司	Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
JP2019513224A (en) *	2016-03-04	2019-05-23	エヌジーエムバイオファーマシューティカルス，インコー	Compositions and methods for adjusting weight
JP7021099B2 (en)	2016-03-31	2022-02-18	エヌジーエムバイオファーマシューティカルス，インコーポレーテッド	Bound protein and how to use it
WO2018071493A1 (en) *	2016-10-12	2018-04-19	Janssen Biotech, Inc.	Methods for screening for modulators of gdf15-like biological activity
TWI724392B (en)	2018-04-06	2021-04-11	美商美國禮來大藥廠	Growth differentiation factor 15 agonist compounds and methods of using the same
CN113226351A (en) *	2018-10-22	2021-08-06	詹森药业有限公司	Glucagon-like peptide 1(GLP1) -growth differentiation factor 15(GDF15) fusion proteins and uses thereof
EP4041722A4 (en)	2019-10-07	2023-12-13	Kallyope, Inc.	Gpr119 agonists
MX2022014505A (en)	2020-05-19	2022-12-13	Kallyope Inc	Ampk activators.
AU2021284131A1 (en) *	2020-06-04	2023-02-09	Daegu Gyeongbuk Institute Of Science And Technology	GFRAL-antagonistic antibody and use thereof
AU2021297323A1 (en)	2020-06-26	2023-02-16	Kallyope, Inc.	AMPK activators
US20240182585A1 (en)	2021-03-31	2024-06-06	Cambridge Enterprise Limited	Therapeutic inhibitors of gdf15 signalling
WO2023274276A1 (en) *	2021-06-30	2023-01-05	上海津曼特生物科技有限公司	Anti-gfral antibody and application thereof
CN118580334A (en) *	2023-03-03	2024-09-03	北京志道生物科技有限公司	Polypeptide molecule
WO2024201293A1 (en) *	2023-03-31	2024-10-03	Università Degli Studi Di Roma "La Sapienza"	Gfral receptor inhibitor for use in the treatment of amyotrophic lateral sclerosis
CN116444667B (en) *	2023-06-13	2023-09-01	上海驯鹿生物技术有限公司	GDF 15-targeted fully-humanized antibody and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003076569A2 (en) *	2002-03-05	2003-09-18	Genentech, Inc.	Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
EP2694092A2 (en) *	2011-04-08	2014-02-12	Amgen Inc.	Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017121865A1 (en) *	2016-01-15	2017-07-20	Novo Nordisk A/S	Mic-1 receptor and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101854947A (en) *	2007-08-16	2010-10-06	圣文森特医院悉尼有限公司	Be used to regulate active medicament of macrophage inhibition factor (MIC-1) and method
CN102321173B (en) *	2011-08-12	2013-04-03	中国医学科学院肿瘤研究所	Humanized macrophage inhibitory factor 1 monoclonal antibody and application thereof
JO3462B1 (en) *	2012-08-22	2020-07-05	Regeneron Pharma	Human Antibodies to GFR?3 and methods of use thereof
WO2014100689A1 (en) *	2012-12-21	2014-06-26	Aveo Pharmaceuticals, Inc.	Anti-gdf15 antibodies

2016
- 2016-02-29 EP EP16891935.5A patent/EP3423094A4/en not_active Withdrawn
- 2016-02-29 WO PCT/CN2016/074809 patent/WO2017147742A1/en active Application Filing
- 2016-02-29 CN CN201680082844.2A patent/CN108697795A/en active Pending
- 2016-02-29 JP JP2018540415A patent/JP2019510739A/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003076569A2 (en) *	2002-03-05	2003-09-18	Genentech, Inc.	Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
EP2694092A2 (en) *	2011-04-08	2014-02-12	Amgen Inc.	Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017121865A1 (en) *	2016-01-15	2017-07-20	Novo Nordisk A/S	Mic-1 receptor and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017147742A1 *
VICKY W. W. TSAI ET AL: "Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15", JOURNAL OF CACHEXIA, SARCOPENIA AND MUSCLE, vol. 3, no. 4, 31 December 2012 (2012-12-31), pages 239 - 243, XP055105895, ISSN: 2190-5991, DOI: 10.1007/s13539-012-0082-6 *

Also Published As

Publication number	Publication date
WO2017147742A1 (en)	2017-09-08
CN108697795A (en)	2018-10-23
JP2019510739A (en)	2019-04-18
EP3423094A1 (en)	2019-01-09

Publication	Publication Date	Title
EP3423094A4 (en)	2019-11-06	Gfral receptor therapies
EP3226856A4 (en)	2018-07-11	Combination therapies
EP3212231A4 (en)	2018-03-28	Anti-tim-3 antibodies
EP3212229A4 (en)	2018-06-27	Anti-tim-3 antibodies
EP3224261A4 (en)	2018-05-16	Opioid receptor modulators
EP3253208A4 (en)	2018-08-15	Combination therapies
EP3459756A4 (en)	2019-11-27	Counterfeit-preventing structure
EP3177650A4 (en)	2018-01-03	Anti-ceramide antibodies
EP3204042A4 (en)	2018-06-06	Psma-related therapies
EP3358740A4 (en)	2019-06-05	Vibrating structure
EP3224230A4 (en)	2018-07-18	Estrogen receptor modulators
AU2016904682A0 (en)	2016-12-01	Construction System Components
AU2016903803A0 (en)	2016-10-06	Putt-N-Pal
AU2016903627A0 (en)	2016-09-22	ShishiaPlus
AU2016903439A0 (en)	2016-09-08	Thermobrush
AU2016903334A0 (en)	2016-09-08	FittConnect
AU2016903303A0 (en)	2016-09-01	Gyrostabilisers
AU2016903360A0 (en)	2016-09-08	Eza-foot
AU2016903171A0 (en)	2016-08-25	postpull
AU2016903133A0 (en)	2016-08-25	Blocksock
AU2016903015A0 (en)	2016-08-11	BootOver
AU2016902910A0 (en)	2016-08-04	BoardCarry
AU2016902711A0 (en)	2016-07-28	Reflect-A-Coat
AU2016901615A0 (en)	2016-05-12	Attached
AU2016902439A0 (en)	2016-07-07	Polybat

Legal Events

Date	Code	Title	Description
2017-09-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-12-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-12-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-01-09	17P	Request for examination filed	Effective date: 20181001
2019-01-09	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-01-09	AX	Request for extension of the european patent	Extension state: BA ME
2019-06-05	DAV	Request for validation of the european patent (deleted)
2019-06-05	DAX	Request for extension of the european patent (deleted)
2019-11-06	A4	Supplementary search report drawn up and despatched	Effective date: 20191009
2019-11-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/395 20060101AFI20191002BHEP Ipc: A61K 45/06 20060101ALI20191002BHEP Ipc: A61K 38/17 20060101ALI20191002BHEP Ipc: A61P 3/04 20060101ALI20191002BHEP Ipc: A61P 3/08 20060101ALI20191002BHEP Ipc: A61P 3/10 20060101ALI20191002BHEP
2020-10-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-11-11	18D	Application deemed to be withdrawn	Effective date: 20200603